{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-029503","form_type":"8-K","ticker":"LFMD","cik":"0000948320","company_name":"LifeMD, Inc.","filed_at":"2026-06-22T12:25:56+00:00","discovered_at":"2026-06-22T12:30:01.467010+00:00","generated_at":"2026-06-22T12:30:11.491487+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"LifeMD partners with Halozyme for exclusive telehealth co-marketing of XYOSTED, launching July 2026 in 37 states","bullets":["LifeMD will be the exclusive telehealth co-marketing partner for XYOSTED (testosterone enanthate) self-pay program.","Program launches July 2026; initially available in 37 states with a transparent $249/month all-inclusive price.","LifeMD's affiliated medical group will evaluate patients, and its pharmacy will be the preferred dispensing pharmacy.","Three-year initial term with automatic renewal; either party can terminate if co-marketing budget missed for two consecutive quarters.","Companies will jointly invest in consumer education and promotional initiatives to expand awareness of hypogonadism."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-029503","json":"https://secwatch.observer/filing/0001493152-26-029503.json","markdown":"https://secwatch.observer/filing/0001493152-26-029503.md","text":"https://secwatch.observer/filing/0001493152-26-029503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/948320/000149315226029503/0001493152-26-029503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/948320/000149315226029503/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T12:30:11.491487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}